Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Astria Therapeutics, Inc. - Common Stock (NQ:ATXS)

12.58 UNCHANGED
Last Price Updated: 4:00 PM EST, Jan 22, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Astria Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
Astria Therapeutics to Present at Upcoming 2025 HAEi Regional Conference EMEA
From Astria Therapeutics, Inc.
Via Business Wire
News headline image
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Astria Therapeutics, Inc.
Via Business Wire
News headline image
Astria Therapeutics Announces Positive Initial Results from the Phase 1a Healthy Subject Trial of STAR-0310 at the European Academy of Dermatology and Venereology
From Astria Therapeutics, Inc.
Via Business Wire
News headline image
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Astria Therapeutics, Inc.
Via Business Wire
News headline image
Astria Therapeutics to Present Initial Data from Phase 1a Trial of STAR-0310 at Upcoming European Academy of Dermatology & Venereology Congress 2025
From Astria Therapeutics, Inc.
Via Business Wire
News headline image
Astria Therapeutics to Present at Upcoming Cantor Global Healthcare Conference
From Astria Therapeutics, Inc.
Via Business Wire
News headline image
Astria Therapeutics Inc (NASDAQ:ATXS) Reports Narrower-Than-Expected Q2 2025 Loss and Strong Cash Runway ↗
Astria Therapeutics reports Q2 2025 results with a narrower-than-expected loss, extended cash runway, and progress in clinical trials for navenibart and STAR-0310. 
Via Chartmill
News headline image
Astria Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Corporate Update
From Astria Therapeutics, Inc.
Via Business Wire
News headline image
Astria Therapeutics Enters into Licensing Agreement with Kaken Pharmaceutical to Develop and Commercialize Navenibart for HAE in Japan
From Astria Therapeutics, Inc.
Via Business Wire
News headline image
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Astria Therapeutics, Inc.
Via Business Wire
News headline image
Astria Therapeutics to Present at Upcoming 2025 US Hereditary Angioedema Association National Summit
From Astria Therapeutics, Inc.
Via Business Wire
News headline image
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Astria Therapeutics, Inc.
Via Business Wire
News headline image
Astria Therapeutics to Participate in Upcoming Oppenheimer Innovators in Immunology & Inflammation Summit
From Astria Therapeutics, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Astria Therapeutics Announces Positive Initial Results from the ALPHA-SOLAR Long-Term Open-Label Trial of Navenibart in Hereditary Angioedema Patients at the European Academy of Allergy and Clinical Immunology Annual Congress
From Astria Therapeutics, Inc.
Via Business Wire
News headline image
Astria Therapeutics to Present at Upcoming European Academy of Allergy and Clinical Immunology Annual Congress
From Astria Therapeutics, Inc.
Via Business Wire
News headline image
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Astria Therapeutics, Inc.
Via Business Wire
News headline image
Astria Therapeutics to Present at Upcoming Jefferies Global Healthcare Conference
From Astria Therapeutics
Via Business Wire
News headline image
Astria Therapeutics to Present at Upcoming C1 Inhibitor Deficiency and Angioedema Workshop
From Astria Therapeutics, Inc.
Via Business Wire
News headline image
Astria Therapeutics to Present at Upcoming Eastern Allergy Conference
From Astria Therapeutics
Via Business Wire
News headline image
Astria Therapeutics Reports First Quarter 2025 Financial Results and Provides a Corporate Update
From Astria Therapeutics, Inc.
Via Business Wire
News headline image
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Astria Therapeutics, Inc.
Via Business Wire
News headline image
Astria Therapeutics Announces Publication of Navenibart Phase 1a Healthy Subject Results in the Annals of Allergy, Asthma & Immunology
From Astria Therapeutics, Inc.
Via Business Wire
News headline image
Astria Therapeutics to Present at Upcoming Citizens Life Sciences Conference
From Astria Therapeutics, Inc.
Via Business Wire
News headline image
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Astria Therapeutics, Inc.
Via Business Wire
News headline image
Astria Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update
From Astria Therapeutics, Inc.
Via Business Wire
News headline image
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Astria Therapeutics, Inc.
Via Business Wire
News headline image
Astria Therapeutics Initiates ALPHA-ORBIT Phase 3 Pivotal Trial of Navenibart in Hereditary Angioedema
From Astria Therapeutics, Inc.
Via Business Wire
News headline image
Astria Therapeutics to Present at Upcoming TD Cowen 45th Annual Health Care Conference
From Astria Therapeutics, Inc.
Via Business Wire
News headline image
Astria Therapeutics to Present at Upcoming American Academy of Allergy, Asthma and Immunology and World Allergy Organization Joint Congress
From Astria Therapeutics, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.